A groundbreaking study involving over 21,000 participants reveals encouraging news for women's brain health. Estrogen-only hormone therapy, when used later in life, has been associated with significantly fewer signs of Alzheimer’s disease and a reduced likelihood of dementia.
A large and inspiring new study has brought encouraging news for women's long-term brain health, suggesting a potential link between estrogen-only hormone therapy and a reduced risk of Alzheimer's disease. The comprehensive research, which included over 21,000 participants, found that women who utilized this therapy later in life were significantly less likely to develop dementia and exhibited fewer tell-tale signs of Alzheimer's within their brains.
The findings are particularly noteworthy, showing that hormone therapy use was associated with a remarkable 39% lower probability of receiving a dementia diagnosis. Furthermore, post-mortem examinations revealed a 35% reduced likelihood of encountering Alzheimer’s-related brain changes, such as the infamous amyloid plaques and tau tangles, among those who had undergone hormone therapy. This hopeful correlation was further supported by biomarker tests, which indicated a decreased buildup of amyloid among the hormone therapy users. This extensive study illuminates a promising path forward in understanding and potentially mitigating the challenges of age-related cognitive decline for women.
Source: ScienceDaily